Key Stats for CVS Health Stock
- 52-Week Range: $59 to $98
- Current Price: $96
- Street Mean Target: $103
- Street High Target: $140
- Analyst Consensus: 18 Buys, 6 Outperforms, 4 Holds
- TIKR Model Target (Dec. 2030): $128
CVS Health Stock Beats Q1 by $0.37 Per Share as Aetna Finally Delivers
CVS Health (CVS) posted Q1 2026 adjusted EPS of $2.57, beating the consensus estimate by $0.37, its fifth consecutive quarterly beat, as the Aetna insurance business produced a medical benefit ratio well below expectations and the company raised full-year guidance to a midpoint that already sits above where Wall Street had priced the year.
The stock surged over 9% on the results.
The number Wall Street had been waiting on was the MBR, the percentage of premiums paid out as medical claims, which Aetna posted at 84.6% in Q1 2026, down from 87.3% in the year-ago quarter and comfortably below analyst estimates around 88%.
That improvement drove Health Care Benefits adjusted operating income to approximately $3 billion in the quarter, a meaningful year-over-year recovery as the company progressed through its second year of margin restoration at Aetna following a period of severe cost underestimation.
Health Services, the segment housing CVS Caremark, the nation’s largest pharmacy benefit manager, generated revenue of over $48 billion in Q1, up 11% year over year, driven primarily by pharmacy drug mix and brand inflation, though adjusted operating income in the segment decreased about 7% as client price improvements continued to flow through.
In the Pharmacy and Consumer Wellness segment, same-store pharmacy sales grew over 3% in the quarter, with same-store prescription volumes up nearly 7%, and the company’s retail script share exceeded 29%.
Revenue for the quarter came in at $100.43 billion, topping the consensus estimate of $95.09 billion.
“We entered 2026 with strong momentum and our intentional execution and deliberate actions across CVS Health have led to another quarter of excellent performance,” CEO David Joyner said on the Q1 2026 earnings call. “We’re improving our capability of forecasting, so the cost trend did not surprise me.”
CVS now guides for full-year 2026 revenue of at least $405 billion, full-year adjusted EPS of $7.30 to $7.50, and cash flow from operations of at least $9.5 billion.
Following the quarter, CVS Health stock received a wave of target price increases, with Piper Sandler moving to $113, Truist raising to $108, Mizuho to $110, JP Morgan to $111, and Bernstein, which reiterated its outperform and moved to $106, calling Aetna’s recovery “proceeding effectively” and projecting the unit’s earnings nearly doubling over the next three years.
CVS also secured a legal win in late May when a Florida judge ruled in favor of CVS, Walgreens, and Walmart in an opioid lawsuit brought by 16 Florida hospitals, removing one litigation overhang that had weighed on the shares.
On the formulary front, CVS Caremark announced it will restore Eli Lilly’s Zepbound to its commercial formularies as a preferred option on October 1, giving CVS’s roughly 90 million covered patients access to both major GLP-1 weight-loss therapies and establishing a competitive pricing dynamic that management expects to drive 10% to 15% in additional savings for clients across the GLP-1 category.
CVS Stock Consensus Is Bullish and the Target Gap Tells the Whole Story
The recovery in Aetna’s medical cost ratio was not a seasonal fluke, and the analyst community has rewarded that conclusion with a consensus that has grown more decisive since Q1 results.
As of June 5, 2026, CVS Health stock carries 18 Buy ratings, 6 Outperforms, and 4 Holds, with zero sells in the coverage universe.
The Street mean target sits at around $103 against a current price of around $96, implying roughly 7% upside from here on the consensus alone.
The Street high target of $140 implies roughly 46% upside from current levels.
The forward earnings picture is where the conviction is anchored: consensus EPS for Q2 2026 is around $1.83, building to around $2.75 for Q1 2027, reflecting continued margin normalization at Aetna as the company moves toward its stated goal of reaching target margins in 2028.
The EBITDA trajectory reinforces the direction: Q1 2026 EBITDA came in at $5.82 billion, up roughly 11% year over year, and estimates for the Q2 2026 period sit at around $4.58 billion, expected to build through the year.
Bernstein described the setup plainly, noting it sees Aetna earnings nearly doubling over the next three years as Medicare Advantage margins continue to normalize through disciplined pricing, a forecast that would make the current EPS range look conservative relative to the earnings power the business can generate at target margins.
The residual risk is real: management has maintained a “cautious view” for the remainder of 2026, acknowledging that elevated cost trends are not yet fully resolved and that 2027 Medicare Advantage rates remain insufficient to offset underlying medical cost pressure, requiring further pricing actions or benefit changes.
The catalyst that could close the remaining gap between the mean target and the current price is Q2 results, where the MBR will be tested without the favorable prior-year development that benefited Q1, and where the Street will be watching whether the 84.6% MBR was a durable result or a seasonally favorable quarter.
At around $96, with a five-quarter streak of earnings beats and a raised guidance range, CVS Health stock is priced for continued execution, not for the full earnings power recovery Bernstein and others have modeled.
Is CVS Health Stock Undervalued in 2026? TIKR’s $128 Mid-Case Says Yes
TIKR’s base case values CVS Health at approximately $128 by December 2030, implying roughly 34% total return from the current price of around $96, or approximately 7% annualized over approximately 4 and a half years.
The scenario breakdown from the TIKR model spans a meaningful range.
If CVS delivers revenue growth in the low case around 4% per year alongside a net income margin near 2.5% and EPS growth around 8% per year, the model produces a stock price near $147 by the end of the forecast period, representing roughly 53% total return and around 5% annualized.
The mid case, anchored at around 4% revenue growth, a net income margin near 3%, and EPS growth around 9% per year, drives the stock to approximately $182 over the full model horizon, representing roughly 90% total return and approximately 8% annualized.
If execution accelerates toward the high case with revenue growth near 5%, a net income margin near 3%, and EPS growth around 10% per year, the model target reaches approximately $218, representing roughly 127% total return and around 10% annualized.
The mid-case price target of $128 at end of 2030 implies CVS Health stock is undervalued by roughly 33% at the current price, before the Street’s longer-term recovery thesis has had time to materialize.
What happened to CVS Health stock after Q1 2026 earnings?
CVS Health stock surged over 9% on May 6, 2026 after the company reported Q1 adjusted EPS of $2.57, beating estimates by $0.37, and raised full-year 2026 guidance to $7.30–$7.50 per share.
The primary driver was Aetna’s medical benefit ratio dropping to 84.6% from 87.3% in the prior year, which pushed Health Care Benefits adjusted operating income to approximately $3 billion for the quarter.
What is the price target for CVS stock?
As of June 5, 2026, the Street mean target for CVS Health stock is around $103, with a high target of $140. The TIKR model mid-case target is approximately $128 by December 2030.
Analysts at Piper Sandler have a $113 target, JP Morgan sits at $111, and Mizuho and Truist have targets at $110 and $108, respectively.
Is CVS Health stock undervalued?
Based on the TIKR mid-case model, CVS Health stock trades at roughly a 33% discount to the estimated fair value of approximately $128 by end of 2030.
The Street mean target of around $103 implies roughly 7% near-term upside. Analyst consensus is 18 Buys, 6 Outperforms, and 4 Holds, with no sell ratings in the coverage universe.
Should You Invest in CVS Health Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CVS Health Corporation stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track CVS Health Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze CVS stock on TIKR for Free →
